Prognostic implications of left ventricular mass-geometry in patients with no or nonobstructive coronary artery disease by Choi, You-Jung et al.
Choi et al. BMC Cardiovasc Disord          (2021) 21:187  
https://doi.org/10.1186/s12872-021-02005-6
RESEARCH
Prognostic implications of left ventricular 
mass-geometry in patients with no or 
nonobstructive coronary artery disease
You‑Jung Choi1, Jun‑Bean Park1,2*, Chan Soon Park1,3, Inchang Hwang1,4, Yeonyee E. Yoon2,4, Seung‑Pyo Lee1,2, 
Hyung‑Kwan Kim1,2, Yong‑Jin Kim1,2, Goo‑Yeong Cho2,4 and Dae‑Won Sohn1,2 
Abstract 
Background: Coronary computed tomography angiography (CCTA) is widely used as a first‑line noninvasive modal‑
ity that frequently exhibits no or nonobstructive coronary artery disease (CAD) in clinical practice, along with abnor‑
mal left ventricular (LV) geometry on echocardiography. However, the combined prognostic value of these findings 
has not been well elucidated. Therefore, we aimed to evaluate the prognostic implications of abnormal LV geometry 
in individuals with no or nonobstructive CAD.
Methods: A total of 5806 subjects with no CAD or nonobstructive CAD (luminal narrowing < 50%) on CCTA were 
included in the study. The major exclusion criteria were structural heart disease and a history of myocardial infarction 
or coronary revascularization. Abnormal LV geometry on echocardiography was defined as LV mass index > 95 g/m2 in 
women and > 115 g/m2 in men, and/or relative wall thickness > 0.42. The primary outcome was all‑cause mortality.
Results: A total of 5803 subjects without significant obstructive CAD (age, 56.6 ± 8.87 years; men, 3884 [66.9%]). Of 
them, 4045 (69.7%) subjects had normal LV geometry and 1758 (30.3%) had abnormal LV geometry respectively. Dur‑
ing a mean follow‑up of 6.2 ± 1.48 years, 84 (1.44%) subjects died in the study population. Of these, 56 subjects were 
from the normal LV geometry group (1.24%) and 28 were from the abnormal LV geometry group (2.32%). Subjects 
with abnormal LV geometry had significantly worse survival rates (log‑rank, p < 0.001). After adjustment for confound‑
ing factors, abnormal LV geometry was an independent predictor of all‑cause mortality (adjusted hazard ratio, 1.64; 
95% confidence interval, 1.04–2.58; p = 0.034). Moreover, abnormal LV geometry was significantly worse in survival 
when classified as those with no CAD (log‑rank, p = 0.024) and nonobstructive CAD (Log‑rank, p < 0.001).
Conclusions: Abnormal LV geometry portends a worse prognosis in subjects with no or nonobstructive CAD. These 
findings suggest that LV geometry assessment can help improve the stratification of individuals with these CCTA 
findings.
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Background
The emergence of coronary computed tomography angi-
ography (CCTA) as a noninvasive imaging modality has 
made it possible to diagnose coronary artery disease 
(CAD) with excellent sensitivity (90–95%) and nega-
tive predictive value (93%–98%) [1]. In addition to these 
Open Access
*Correspondence:  nanumy1@gmail.com
1 Division of Cardiology, Department of Internal Medicine/Cardiovascular 
Center, Seoul National University Hospital, 101 Daehak‑ro, Jongno‑gu, 
Seoul 03080, Republic of Korea
Full list of author information is available at the end of the article
Page 2 of 9Choi et al. BMC Cardiovasc Disord          (2021) 21:187 
advantages, CCTA has been widely used to detect or 
exclude significant CAD, serving as a reliable gatekeeper 
for invasive coronary angiography. Consequently, in 
clinical practice, no CAD or nonobstructive CAD is fre-
quently encountered on CCTA.
In previous studies, the prognostic importance of non-
obstructive CAD has been substantiated already [2, 3]. 
Indeed, subsequent aggressive preventive interventions 
have been emphasized for patients with nonobstruc-
tive CAD than those without CAD [4, 5]. A recent study 
reported that nonobstructive CAD incidentally found on 
CCTA in the emergency department increases the likeli-
hood of statin prescription [6]. The CCTA-based assess-
ment of plaque size and its composition has recently 
gained particular attention as an imaging method to 
improve risk stratification and ultimately further statin 
allocation since this technique seems to enable the risk 
prediction of cardiovascular disease events in patients 
with nonobstructive CAD [7]. However, due to technical 
challenges in the analysis of plaque characteristics, it has 
not become a part of real-world clinical practice, suggest-
ing the need for more readily available tests on a routine 
clinical basis.
Left ventricular (LV) hypertrophy is a consequence 
of cardiac geometric adaptation in response to sys-
temic hemodynamics and ventricular load [8]. Abnor-
mal LV geometric patterns are associated with systolic 
and diastolic dysfunction [9] and, more importantly, are 
well-established predictors of cardiovascular morbidity 
and mortality in various populations [10–13]. However, 
there is a paucity of data to inform the prognostic value 
of abnormal LV geometry for no or nonobstructive CAD 
detected by CCTA. Therefore, the current study aimed to 
evaluate the prognostic implication of echocardiography-
determined LV geometry in individuals without obstruc-
tive CAD confirmed by CCTA.
Methods
Study design and patients
This was an observational retrospective multicenter 
cohort study. We reviewed 12,956 consecutive subjects 
who underwent CCTA and echocardiography between 
2002 and 2011 at the Seoul National University Hospi-
tal, Seoul National University Bundang Hospital, and 
Seoul National University Hospital Gangnam Center. We 
excluded individuals with significant LV systolic dysfunc-
tion (defined as ejection fraction < 40%), hypertrophic or 
infiltrative cardiomyopathy, severe valvular heart disease, 
and those with a history of previous myocardial infarc-
tion, coronary revascularization, or cardiac surgery.
A total of 5803 subjects were included in the final anal-
ysis, who had available echocardiographic data on the left 
ventricular mass index (LVMI) and relative wall thickness 
(RWT) and had no significant coronary artery stenosis 
(defined as luminal narrowing < 50%) on CCTA (Addi-
tional file  1: Fig.  1). The date of the final follow-up was 
March 18, 2016.
The study protocol was approved by the Institutional 
Review Board of Seoul National University Hospital (IRB 
No. J-1511-025-715), and was performed in accordance 
with the Declaration of Helsinki. Written informed con-
sent was waived owing to the retrospective and observa-
tional nature of this study.
Image acquisition and analysis for CCTA 
Electrocardiographic-gated CCTA images were acquired 
using a 64-slice multidetector scanner (SOMATOM 
Sensation 64, SOMATOM Definition, Siemens Medical 
Solutions, Forchheim, Germany; Brilliance 64, Philips 
Medical Systems, Best, The Netherlands). Before per-
forming the scan, sublingual nitroglycerine (0.3 mg) was 
administered to provide transient coronary dilatation, 
and metoprolol (50  mg) was administered to subjects 
presenting with a heart rate of more than 60  beats per 
minute. The CCTA results were graded as none (lumi-
nal narrowing, 0%), nonobstructive (luminal narrow-
ing, 1–49%), and obstructive (luminal narrowing ≥ 50%) 
respectively based on the severity of narrowing in any of 
the major epicardial coronary arteries.
Echocardiographic analysis
All patients underwent comprehensive two-dimensional 
echocardiography within 3  months of initial CCTA. 
Hypertrophic alteration of the LV structure was quanti-
fied based on LVMI and RWT by echocardiography [14]. 
LVMI was estimated using a standard formula with LV 
cavity dimension and wall thickness at end-diastole and 
indexed to body surface areas. Linear internal measure-
ment of the LV and its wall was performed in the par-
asternal long-axis view, and the values were obtained 
perpendicular to the long axis of the LV at or immediately 
below the level of the mitral valve leaflet tips [14]. LV 
mass index was calculated using the following equation:
1. LV mass = 0.8 × 1.04 × {[LV end-diastolic dimen-
sion (LVEDD) + interventricular septal wall thick-
ness + LV posterior wall  thickness]3 −  LVEDD3} + 0.6
2. LV mass index = LV mass/body surface area
RWT was calculated as two times the posterior wall 
thickness divided by the LV diastolic diameter. Increased 
LVMI was defined as LVMI > 95  g/m2 in women 
and > 115  g/m2 in men, and the cutoff for abnormal 
RWT was > 0.42, in both women and men [14]. Normal 
LV geometry was defined as normal LVMI and RWT. 
Abnormal LV geometry was defined as a composite of 
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concentric remodeling (normal LVMI and increased 
RWT), eccentric hypertrophy (increased LVMI and nor-
mal RWT), and concentric hypertrophy (increased LVMI 
and RWT).
Laboratory tests
Using electronic medical records, we obtained laboratory 
information, including serum hemoglobin, total choles-
terol, triglycerides, low-density lipoprotein cholesterol, 
high-density lipoprotein cholesterol, fasting blood glu-
cose, creatinine, and estimated glomerular filtration rate 
(eGFR) accordingly for all the patients.
Primary outcome
The primary outcome was all-cause mortality. Mortality 
data were obtained and verified via a centralized database 
of death records from the Korean Ministry of Security 
and Public Administration.
Statistical analysis
Descriptive data were reported as mean ± standard 
deviation for continuous variables and as numbers and 
percentages for categorical variables. Shapiro–Wilk 
Normality test was performed to determine the distri-
bution of data. We performed the Student’s t-test and 
Mann–Whitney U test for continuous variables accord-
ing to the data distribution and Chi-square test for cate-
gorical variables for the comparison between normal and 
abnormal LV geometry groups. Further, a  comparison 
of mean values between multiple groups was performed 
using one-way analysis of variance, and Kruskal–Wal-
lis tests were used for continuous variables according to 
the data distribution, and the chi-squared test was per-
formed for categorical variables, followed by a post-hoc 
comparison. Event-free survival analysis was performed 
using the Kaplan–Meier method and compared using the 
log-rank test. To investigate the association between LV 
geometry and all-cause mortality, hazard ratios (HRs) 
and 95% confidence intervals (CIs) were calculated using 
univariate and multivariate Cox proportional regression 
analyses. Multivariate analysis adjusting for statistically 
different baseline variables (age, sex, body mass index, 
serum hemoglobin, serum total cholesterol, and eGFR) 
was performed to provide independent effect estimates 
for abnormal LV geometry on the primary outcome.
A two-tailed p value of < 0.05, was considered statisti-
cally significant. All statistical analyses were performed 
using SPSS version 23 (IBM Corp, Chicago, IL, USA) 
and R programming version 3.2.4 (http:// www.R- proje ct. 
org; The R Foundation for Statistical Computing, Vienna, 
Austria).
Results
Baseline characteristics of the study population
A total of 5803 subjects without significant obstructive 
CAD consisted of 3884 (66.9%) men with a mean age of 
56.6 ± 8.87  years (Table  1). Of them, 4045 (69.7%) sub-
jects had normal LV geometry and 1758 (30.3%) had 
abnormal LV geometry. The subjects with normal LV 
geometry were younger than those with abnormal LV 
geometry (55.7 ± 8.68 vs. 58.5 ± 8.98  years, p < 0.001), 
and this was observed more frequently in men (69.6 vs. 
65.9%, p < 0.001). There was no significant difference in 
the baseline laboratory results between the two groups, 
except for the decreased hemoglobin (14.4 ± 1.61  mg/
dL in normal geometry vs. 14.6 ± 1.45  mg/dL in abnor-
mal geometry, p < 0.001) and eGFR levels (77.2 ± 13.7 vs. 
78.8 ± 13.3  mL/min/1.73  cm2, p < 0.001). With regard to 
echocardiographic parameters, the abnormal LV geom-
etry group had increased LV wall thickness and cham-
ber size, but also larger left atrial size (36.5 ± 4.95  mm 
vs. 38.0 ± 5.48  mm, p < 0.001), higher pulmonary artery 
systolic pressure (27.0 ± 4.63 vs. 28.1 ± 5.06  mmHg, 
p < 0.001), and a higher ratio of peak early transmitral 
inflow velocity to early diastolic velocity of the mitral 
annulus (E/e’) (9.34 ± 2.84 vs. 11.4 ± 2.05, p = 0.003) than 
the normal LV geometry group. The baseline character-
istics according to the four LV geometric patterns are 
shown in Additional file 1: Table 1.
Association between abnormal LV geometry and all‑cause 
mortality
During a mean follow-up of 6.2 ± 1.48 years, 84 (1.44%) 
subjects died in the study population. Of these, 56 sub-
jects were from the normal LV geometry group (1.24%) 
and 28 were from the abnormal LV geometry group 
(2.32%). After adjustment for confounding factors, 
abnormal LV geometry was independently associated 
with an increased risk of all-cause mortality (adjusted 
HR 1.64; 95% CI, 1.02–2.67; p = 0.040) (Table  2). In the 
Kaplan–Meier survival analysis, the abnormal LV geom-
etry group showed a worse prognosis than the normal LV 
geometry group (log-rank p < 0.001) (Fig. 1). In the sub-
group analysis, the impact of abnormal LV geometry on 
all-cause mortality was directionally consistent with that 
in the main analysis (Additional file 1: Table 2).
Clinical impact of abnormal LV geometry in no or 
nonobstructive CAD
We classified subjects into four groups according to the 
joint categories of LV geometry and CAD: 1) normal LV 
geometry with no CAD, 2) normal LV geometry with 
nonobstructive CAD, 3) abnormal LV geometry with no 
CAD, and 4) abnormal LV geometry with nonobstructive 
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CAD. Compared to normal LV geometry without CAD, 
abnormal LV geometry without CAD (HR 2.38, 95% CI 
1.41–4.03, p = 0.001) and those with nonobstructive 
CAD (HR: 4.54, 95% CI: 2.42–8.51, p < 0.001) had a higher 
risk of all-cause mortality (Table 3). In the Kaplan–Meier 
survival analysis, abnormal LV geometry had worse 
overall survival in both patients with no CAD (log-rank 
test, p = 0.024) and non-obstructive CAD (log-rank test, 
p < 0.001) (Fig. 2). After adjustment for confounding fac-
tors, abnormal LV geometry with nonobstructive CAD 
remained an independent predictor of all-cause mor-
tality (adjusted HR 2.49; 95% CI, 1.24–4.99; p = 0.010) 
(Table 3).
Association between LV geometry pattern and all‑cause 
mortality
When subjects were stratified into four groups according 
to LV geometric patterns, each abnormal LV geometric 
pattern was associated with an increased risk of all-cause 
mortality compared with normal geometry (log-rank, 
p < 0.001) (Additional file  1: Fig.  2). Eccentric hypertro-
phy carried the highest risk (HR 3.60, 95% CI 1.91–5.91, 
p < 0.001), followed by concentric hypertrophy (HR 2.34, 
95% CI 1.05–5.23, p = 0.037), and concentric remodeling 
(HR 1.92, 95% CI 1.12–3.31, p = 0.019). After adjustment, 
the risk of all-cause mortality was significantly increased 
only in subjects with eccentric hypertrophy (adjusted 
HR 2.29; 95% CI, 1.25–4.18; p = 0.007) (Additional file 1: 
Table 3).
Sensitivity analysis
On repetition of the multivariate Cox proportional 
regression analysis after further adjusting for medica-
tions (beta-blockers and antidiabetic agents) that were 
significantly associated with all-cause mortality in the 
univariate analysis, it was found that abnormal LV geom-
etry remained an independent predictor for the primary 
outcome (HR 1.62; 95% CI, 1.01–2.60; p = 0.019).
Discussion
This study evaluated the prognostic value of abnormal 
LV geometry estimated by echocardiography in individu-
als with no or nonobstructive CAD on CCTA. The main 
findings were as follows: (1) in this cohort with low risk 
for CAD confirmed by CCTA, echocardiography-deter-
mined abnormal LV geometry was associated with an 
increased risk of all-cause mortality; (2) the prognostic 
impact of abnormal LV geometry was consistent in both 
Fig. 1 Kaplan–Meier survival curve for subjects with no or nonobstructive CAD on CCTA according to presence or absence of abnormal LV 
geometry. CAD, coronary artery disease; CCTA, Coronary computed tomography angiography; LV, left ventricular
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Table 1 Baseline characteristics
Values are presented as mean ± SD for continuous variables and as numbers (%) for categorical variables
ARB, angiotensin receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; eGFR, estimated glomerular filtration rate; E/e’, the ratio of peak early transmitral 
inflow velocity to early diastolic velocity of the mitral annulus; HDL, high-density lipoprotein; IVSd, interventricular septum thickness at end-diastole; LDL, low-density 
lipoprotein; LV, left ventricular; PASP, pulmonary artery systolic pressure; PWd, posterior wall thickness at end-diastole; RWT, relative wall thickness
Values Total (n = 5803) Normal geometry (n = 4045) Abnormal Geometry 
(n = 1758)
P value
Age, years 56.6 ± 8.87 55.7 ± 8.68 58.5 ± 8.98  < 0.001
Male sex, n (%) 3884 (66.9) 2816 (69.6) 1068 (65.8)  < 0.001
Body mass index, kg/m2 24.4 ± 2.85 24.3 ± 2.77 24.6 ± 2.99  < 0.001
Medications, n (%)
 Statins 258 (4.4) 176 (4.4) 82 (4.7) 0.644
 ARB/ACEI 243 (4.2) 141 (3.5) 102 (5.8)  < 0.001
 Beta‑blockers 577 (9.9) 246 (8.6) 231 (13.1)  < 0.001
 Antidiabetic agents 224 (3.9) 128 (3.3) 96 (5.5)  < 0.001
Laboratory exam
 Hemoglobin, mg/dL 14.6 ± 15.0 14.6 ± 1.45 14.4 ± 1.61  < 0.001
 Total cholesterol, mg/dL 199 ± 36.1 199 ± 35.8 199 ± 36.8 0.940
 LDL cholesterol, mg/dL 125 ± 33.0 125 ± 33.2 124 ± 32.5 0.356
 HDL cholesterol, mg/dL 52.3 ± 12.9 52.3 ± 12.7 52.1 ± 13.4 0.620
 Triglycerides, mg/dL 127 ± 81.4 127 ± 80.6 128 ± 83.2 0.608
 Fasting blood glucose, mg/dL 103 ± 23.8 102 ± 23.6 104 ± 24.0 0.055
 Creatinine, mg/dL 1.00 ± 0.37 1.02 ± 0.19 1.00 ± 0.60 0.970
 eGFR, ml/min/1.73m2 78.3 ± 13.4 78.8 ± 13.3 77.2 ± 13.7  < 0.001
Echocardiographic parameter
 LV end‑diastolic dimension, mm 48.3 ± 4.03 48.5 ± 3.60 47.6 ± 4.82  < 0.001
 LV end‑systolic dimension, mm 28.4 ± 3.63 28.6 ± 3.37 28.0 ± 4.13  < 0.001
 LV ejection fraction, % 65.1 ± 6.14 65.0 ± 5.94 65.2 ± 6.57 0.270
 Left atrial size, mm 36.9 ± 5.16 36.5 ± 4.95 38.0 ± 5.48  < 0.001
 IVSd, mm 9.19 ± 1.32 8.77 ± 1.07 10.2 ± 1.32  < 0.001
 PWd, mm 9.13 ± 1.32 8.60 ± 1.01 10.3 ± 1.14  < 0.001
 RWT, mm 0.38 ± 0.06 0.36 ± 0.04 0.44 ± 0.06  < 0.001
 LV mass, g 154 ± 38.1 145 ± 31.0 176 ± 43.7  < 0.001
 LV mass index, g/m2 87.7 ± 19.5 81.9 ± 14.0 101.1 ± 23.3  < 0.001
 PASP, mmHg 27.3 ± 4.78 27.0 ± 4.63 28.1 ± 5.06  < 0.001
 E/e’ ratio 9.98 ± 18.1 9.34 ± 2.84 11.4 ± 2.05 0.003
Table 2 Factors associated with all‑cause mortality
*Adjusted for age, male sex, body mass index, total cholesterol, and eGFR
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LV left ventricular
Variables Univariate Multivariate *
HR 95% CI P value HR 95% CI P value
Abnormal LV geometry 2.40 1.563–3.679  < 0.001 1.65 1.022–2.670 0.040
Age, years 1.12 1.093–1.147  < 0.001 1.09 1.054–1.117  < 0.001
Male sex, n (%) 0.99 0.628–1.555 0.957 3.12 1.710–5.709  < 0.001
Body mass index, kg/m2 0.94 0.863–1.016 0.113 0.93 0.853–1.014 0.098
Hemoglobin, mg/dL 0.698 0.613–0.795  < 0.001 0.650 0.544–0.776  < 0.001
Total cholesterol, mg/dL 0.99 0.983–0.996 0.001 1.00 0.993–1.006 0.783
eGFR, ml/min/1.73m2 0.96 0.947–0.979  < 0.001 0.981 0.963–1.000 0.456
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individuals with no CAD and nonobstructive CAD, and 
3) eccentric hypertrophy carried the greatest risk of all-
cause mortality among different types of abnormal LV 
geometry.
The presence, extent, and severity of CAD confirmed 
by CCTA have been well recognized as a strong predictor 
of adverse outcomes, including death, myocardial infarc-
tion, and late revascularization [15, 16]. In this regard, 
CCTA is widely used as a noninvasive imaging modality 
for detecting atherosclerotic coronary disease in individ-
uals at low to intermediate risk of cardiovascular disease 
[17, 18], despite its potential risks, such as overdiagnosis, 
overtreatment, and unnecessary medical costs [19]. It has 
been reported that individuals without CAD confirmed 
by CCTA have a favorable long-term prognosis [20, 21]. 
In the Coronary CT Angiography Evaluation for Clinical 
Outcomes: An International Multicenter Registry (CON-
FIRM) study of 7590 asymptomatic individuals, obstruc-
tive CAD also carries a higher risk of mortality and 
composite outcomes than those with no CAD confirmed 
by CCTA [19]. Although the prognostic importance of 
nonobstructive CAD has been underappreciated, sev-
eral studies have recently shown that nonobstructive 
CAD confirmed by CCTA is associated with increased 
Table 3 Risk of all‑cause mortality according to LV geometry and CAD on CCTA 
*Adjusted for age, male sex, body mass index, hemoglobin, total cholesterol, and estimated glomerular filtration rate
CAD, coronary artery disease; CCTA, Coronary computed tomography angiography; CI, confidence interval; HR, hazard ratio; LV left ventricular
Subgroup Unadjusted Adjusted*
HR 95% CI P value HR 95% CI P value
Normal LV geometry with no CAD Reference – Reference
Normal LV geometry with nonobstructive CAD 2.040 1.055–3.943 0.340 1.687 0.919–3.096 0.091
Abnormal LV geometry with no CAD 2.385 1.412–4.028 0.001 1.656 0.830–3.303 0.153
Abnormal LV geometry with nonobstructive CAD 4.541 2.423–8.511  < 0.001 2.492 1.244–4.990 0.010
Fig. 2 Kaplan–Meier survival curve for subjects with no or nonobstructive CAD on CCTA according to joint categories of LV geometry and CAD 
status. CAD, coronary artery disease; CCTA, Coronary computed tomography angiography; LV, left ventricular
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mortality risk in various populations [3, 4, 8]. This find-
ing is of clinical importance because effective treatment 
options, such as statin therapy, are available for patients 
with nonobstructive CAD, which can improve their prog-
nosis [5].
However, the prevalence of nonobstructive CAD is 
substantial, and its prognosis can vary among individ-
ual patients, making it challenging to apply preventive 
or therapeutic measures to patients with nonobstruc-
tive CAD in general. Specifically, in patients with stable 
angina, the prevalence of nonobstructive CAD was 67%, 
with 73% of patients referred to CCTA and 49% among 
those with invasive coronary angiography [19]. Of note, 
the prognosis of patients with nonobstructive CAD dif-
fers according to several factors based on plaque volume 
and characteristics [7, 22]. These findings imply that 
these techniques may be a practical approach allow-
ing the identification of high-risk subgroups of patients 
with nonobstructive CAD who would benefit from more 
intensive monitoring and treatment. However, a recent 
study suggests that whether reporting of CCTA-derived 
plaque characteristics has clinical implications at this 
point remains unclear [23]. Furthermore, the assessment 
of plaque volume and characteristics is challenging to 
perform, particularly as an integral part of routine clini-
cal practice. Therefore, an easy-to-perform and widely 
available method to predict outcomes in patients with 
nonobstructive CAD would be clinically useful in mak-
ing decisions on the management and follow-up of this 
heterogeneous group of patients.
In the present study, we demonstrated that abnormal 
LV geometry determined by echocardiography, which is 
one of the most frequently used imaging tests in the field 
of cardiology, was associated with all-cause mortality in 
individuals with no or nonobstructive CAD confirmed by 
CCTA. Several lines of evidence support the concept that 
LV geometry is an imaging marker integrating long-term 
exposure to both hemodynamic abnormalities (pressure 
and/or volume overload) and non-hemodynamic fac-
tors. Specifically, LV geometry is considered to reflect 
the severity and chronicity of cardiovascular risk factors, 
such as hypertension, diabetes mellitus, dyslipidemia, 
and obesity [24–27], suggesting that LV geometry, as 
an integrated and cumulative indicator, maybe a better 
prognosticator than each of the traditional risk factors. It 
is not surprising that the prognostic role of LV geometry 
has been extensively investigated in various populations, 
including patients referred for coronary angiography due 
to suspected CAD and those following a high-risk myo-
cardial infarction [28]. However, only a few studies have 
described the association between LV geometry and 
outcomes in low-risk patients. In this regard, our study 
showed that individuals with abnormal LV geometry and 
no or nonobstructive CAD had a dismal prognosis com-
pared with others, highlighting the need for more aggres-
sive monitoring and treatment in this subpopulation.
Given that abnormal LV geometry is a time-integrated 
indicator of several risk factors that are active in pro-
moting the progression of coronary atherosclerosis and 
consequently leading to increased adverse clinical out-
comes [29], it can be speculated that progression of CAD 
might be accelerated in individuals with initially no CAD 
if abnormal LV geometry is present. Indeed, our study 
demonstrated that during the first 2  years of follow-up, 
the survival curve of subjects with no CAD but with 
abnormal LV geometry was nearly identical to that of 
subjects with no CAD and normal LV geometry; how-
ever, the survival curves significantly diverged thereafter. 
Conversely, all-cause mortality was lower in subjects with 
no CAD but with abnormal LV geometry than in those 
with nonobstructive CAD but with normal LV geometry 
during the first 2  years of follow-up. Nevertheless, the 
survival curves converged, and the between-group differ-
ences were insignificant at the final follow-up. Our study 
suggested that progression of CAD may be more fre-
quent in individuals with no or nonobstructive CAD who 
have abnormal LV geometry than in those with normal 
LV geometry. Further studies with larger sample sizes 
and longer follow-up durations are needed to confirm 
our results and speculation.
Strengths and limitations
The most compelling advantage of our study is that it is 
a well-constructed, large imaging database study con-
taining both CCTA and echocardiographic images from 
all participants. Furthermore, our study has an advan-
tage over prior research owing to the inclusion of many 
Asians in whom the association of LV geometry with 
prognosis has not been extensively investigated. Specifi-
cally, in the landmark Framingham Heart Study (FHS) by 
Levy et  al. [30], participants were predominantly White 
individuals of Western European descent. Although a 
more ethnically diverse group of individuals is reflected 
in the FHS OMNI cohorts, the proportion of the Asian 
population is only 28% [31], resulting in limited power to 
draw conclusive results. Additionally, considering the rel-
atively low body mass index in our study population, our 
findings might be less confounded by overweight or obe-
sity, which is an important confounding factor in studies 
investigating the association between LV geometry and 
prognosis [32].
However, several limitations should be considered 
when interpreting our findings. First, this was a ret-
rospective observational study with inherent limita-
tions, such as unmeasured confounders. Although 
we adjusted for a set of conventional cardiovascular 
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disease risk factors, residual confounding cannot be 
completely excluded. Second, the exact clinical indica-
tions for CCTA scans were not documented, although 
most individuals underwent CCTA for the identifi-
cation of CAD, owing to the presence of chest pain, 
dyspnea, and cardiovascular risk factors. However, 
since individuals with obstructive CAD confirmed by 
CCTA were excluded from our study, the difference in 
the clinical indications for CCTA scans might not sub-
stantially affect the results of this study. Third, since we 
focused on all-cause mortality as the primary outcome, 
data on specific causes of death were not available. In 
observational studies, all-cause mortality is generally 
considered a more robust and unbiased outcome than 
disease-specific mortality. However, data on the specific 
cause of death might have strengthened the association 
between LV geometry and cardiovascular prognosis in 
subjects with no or nonobstructive CAD. Fourth, there 
remains a possibility that certain conditions affecting 
both LV structure and mortality were not fully ruled 
out. To minimize this concern, we excluded individu-
als with cardiomyopathy and significant valvular heart 
disease from the analyses. Fifth, as Korean individu-
als were exclusively included in the present study, it 
is uncertain whether our findings can be generalized 
to other populations. Lastly, since there are no data 
on noninvasive stress testing, we could not entirely 
exclude the possibility of myocardial ischemia, which is 
clearly a confounding factor related to mortality.
Conclusions
Abnormal LV geometry carried a worse prognosis than 
normal LV geometry in individuals with no or non-
obstructive CAD confirmed by CCTA. These findings 
suggest that the use of echocardiography for LV geom-
etry assessment has the potential to be a clinically use-
ful and practical approach for risk stratification in this 
population.
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